How to leverage novel trial designs and real-world data to support a cancer drug submission with an evidence strategy that is both approvable and reimbursable.
Advancing risk-based auditing one step further by identifying the underlying process deficiencies to enable improved corrective and preventive actions.
Presenting how data transformation is measured as part of the SAFE Data Standard, which data variables influence the rating and, how the appropriate level of data transformation is calculated.
Regulators are urging the use of data monitoring committees to support clinical trial management and decision-making during pandemic.
In this Q&A with Applied Clinical Trials' sister brand, Pharmaceutical Executive, Lofaso discusses marketing strategies for early-stage biotech companies, including how they can effectively recruit patients for their clinical trials.
Laboratory services organization focuses on easing patient and site burden with improved collection device.
Study seeks to understand how different forms of data meet the needs of researchers.
Examining the two areas of weakness cited in FDA draft guidance.
First-of-its-kind consortium dedicated to accelerating new medicines development through optimizing patient advocacy group—industry collaboration.
How Clinical Research Malaysia sped up CTA turnaround using a web-based system.
Differing levels of trust in clinical trials information channels across diverse populations is examined in this research.
The need for specific capabilities to suit DCT business models is creating new challenges in team building, training, and development.
How asking better questions and leveraging site databases can expand access to more patients.
In this playbook, learn how a virtual site solution expands access to infectious disease clinical trials by allowing patients to enroll and participate from anywhere.
A discussion of the impact of a strategic alliance in to facilitate operational success at the clinical trial site level in Malaysia.
Evidence from a Phase III cancer trial points to notable advances in data-transfer tech.
Industry must act now to minimize effects of COVID-19 on clinical research.
Evidence from a Phase III cancer trial points to notable advances in data-transfer tech.
Addressing misconceptions as industry becomes more familiar with AI and ML.
The revision of Annex 1 clearly calls out the use of quality risk management to identify potential risks to quality and the implementation of a contamination control strategy.
The latest FDA and EMA guidelines permit sites, sponsors, and CROs to adjust their operations to meet changing conditions for ongoing trials, including some concerning the safety of participants, that must be met in order for new solutions to be considered.
Bayesian methods bring flexibility and speed to clinical trial design and analysis, and with increased access to the necessary computational power, are transforming today’s clinical research.
Advances in technology open door for improved EHR to EDC transfer process.
Many companies during this time of social distancing have paused trial recruitment completely to focus on currently recruited patients, while others rethink their strategy to better accommodate the new digital-only reality.
January 2023 guidance from FDA on dosages in oncology provides further context on expectations with Project Optimus.
Recent case study highlights the importance of applying statistical rigor throughout the development and validation processes of biomarkers.
New proposals aim to create higher standards for trial regulation.
Approaches sponsors, CROs, and investigators can take from the DMD experience.